All In Biotech

Drug Trial Radar · NCT02452372

A Phase 1 Study of Givosiran (ALN-AS1) in Patients With Acute Intermittent Porphyria (AIP)

A Phase 1, Single-ascending Dose, Multiple-ascending Dose, and Multi-dose Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study of Subcutaneously Administered ALN AS1 in Patients With Acute Intermittent Porphyria (AIP)

Last checked: Nov 20, 2026Latest source record: Jun 14, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

40

Actual

Start

May 6, 2015

Primary completion

Sep 6, 2017

Study completion Sep 6, 2017

Sponsor

Lead sponsor
Alnylam PharmaceuticalsAlnylam Pharmaceuticals (ALNY)
Sponsor type
Industry
First posted
May 22, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Single (participant)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety and tolerability of givosiran (ALN-AS1) in AIP patients as well as to characterize pharmacokinetics (PK) and pharmacodynamics (PD) of ALN-AS1 in AIP patients.

Conditions

  • Acute Intermittent Porphyria

Interventions

  • givosiran (ALN-AS1)Drug

    Single or multiple doses of ALN-AS1 by subcutaneous (sc) injection

  • Sterile Normal Saline (0.9% NaCl)Drug

    calculated volume to match active comparator

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The safety of givosiran evaluated by the proportion of subjects experiencing adverse events (AEs), serious adverse events (SAEs), and AEs leading to study drug discontinuationTime frame: Part A (SAD phase): through day 42; Part B (MAD) phase: through Day 70; Part C (MD) phase: through Day 168

Locations

6 sites in 3 countries. Site status is shown where the registry gives one.

  • Clinical Trial Site

    Birmingham, Alabama

  • Clinical Trial Site

    San Francisco, California

  • Clinical Trial Site

    New York, New York

  • Clinical Trial Site

    Galveston, Texas

  • Clinical Trial Site

    Stockholm, Sweden

  • Clinical Trial Site

    London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.